PHARMACOKINETICS OF CEFPIROME IN BUFFALO CALVES (BUBALUS BUBALIS) FOLLOWING SINGLE INTRAMUSCULAR ADMINISTRATION

-1 , which declined to 0.2 ± 0.1 µg.ml -1 at 24 hrs. The absorption half-life (t1/2Ka) and elimination half-life (t1/2 β) were 0.19 ± 0.03 hr and 2.39 ± 0.05 hr, respectively. The area under the plasma concentration-time curve (AUC), area under the first moment curve (AUMC), apparent volume of distribution (Vdarea), total body clearance (ClB), mean residence time (MRT) and total duration of therapeutic effect (td) were 28.7 ± 1.9 µg.ml -1 .hr, 107.7 ± 6.7 µg.ml -1 .hr 2 , 0.42 ± 0.01 L.kg -1 , 0.12 ± 0.003 L.kg -1 .hr -1 , 3.76 ± 0.04 hr and 12.7 ± 0.3 hr, respectively. The systemic bioavailability (F) after IM administration of cefpirome in calves was 35.3 ± 3.1%. To maintain a minimum therapeutic concentration of 0.25 µg.ml -1 , a satisfactory dosage regimen of

[1]  A. Srivastava,et al.  Comparative pharmacokinetics of cefotaxime in normal cyclic and endometritis affected buffaloes , 2005 .

[2]  M. Zeitlinger,et al.  Pharmacokinetics and Pharmacodynamics of Cefpirome in Subcutaneous Adipose Tissue of Septic Patients , 2005, Antimicrobial Agents and Chemotherapy.

[3]  A. Srivastava,et al.  PHARMACOKINETICS FOLLOWING INTRAMUSCULAR ADMINISTRATION AND DOSAGE REGIMEN FOR CEFOPERAZONE IN BUFFALO CALVES , 2005 .

[4]  N. Klesel,et al.  Pharmacokinetic properties of the new cephalosporin antibiotic HR 810 in animals , 1983, Infection.

[5]  S. Sharma,et al.  Pharmacokinetics and Dosage Regimen of Ceftriaxone in Buffalo Calves , 2004, Veterinary Research Communications.

[6]  S. Sharma,et al.  Pharmacokinetic disposition of cefotaxime in buffalo calves (Bubalus bubalis) following single intramuscular administration , 2004 .

[7]  R. Neubert,et al.  In‐vitro and in‐vivo studies of cefpirom using bile salts as absorption enhancers , 2003, The Journal of pharmacy and pharmacology.

[8]  Harald Herkner,et al.  Closed-chest microdialysis to measure antibiotic penetration into human lung tissue. , 2002, American journal of respiratory and critical care medicine.

[9]  R. K. Chaudhary,et al.  Disposition kinetics and urinary excretion of cefuroxime following intramuscular administration in buffalo calves , 2002 .

[10]  H. Eichler,et al.  Micellar electrokinetic chromatography for the analysis of cefpirome in microdialysis and plasma samples obtained in vivo from human volunteers , 2000, Electrophoresis.

[11]  H. Eichler,et al.  Relationship Between Serum and Free Interstitial Concentrations of Cefodizime and Cefpirome in Muscle and Subcutaneous Adipose Tissue of Healthy Volunteers Measured by Microdialysis , 1997, Journal of clinical pharmacology.

[12]  Y. Kita,et al.  Comparative pharmacokinetics of SCE-2787 and related antibiotics in experimental animals , 1992, Antimicrobial Agents and Chemotherapy.

[13]  G. Seibert,et al.  Pharmacokinetics of cefpirome administered intravenously or intramuscularly to rats and dogs. , 1992, The Journal of antimicrobial chemotherapy.

[14]  T. Sakaguchi,et al.  Distribution of cefpirome (HR 810) to exudate in the croton oil-induced rat granuloma pouch and its therapeutic effects on experimental infections in the pouch , 1988, Antimicrobial Agents and Chemotherapy.

[15]  S. Hayashi,et al.  Beta-lactamase stability of cefpirome (HR 810), a new cephalosporin with a broad antimicrobial spectrum , 1986, Antimicrobial Agents and Chemotherapy.

[16]  J. Wright,et al.  HR 810 and BMY-28142, two new cephalosporins with broad-spectrum activity: an in-vitro comparison with other beta-lactam antibiotics. , 1985, The Journal of antimicrobial chemotherapy.

[17]  D. P. Johnson,et al.  Outline of details for microbiological assays of antibiotics: second revision. , 1971, Journal of pharmaceutical sciences.

[18]  M. Finland,et al.  Distribution and excretion of four tetracycline analogues in normal young men. , 1959, The Journal of clinical investigation.